美国国立卫生研究院对乳腺癌与妇科癌症幸存者研究资助的比较
BACKGROUND: Cancer survivorship in the United States is rapidly rising, with a projected 50% increase by 2050, driven by improvements in treatment and increased incidence of cancers such as endometrial cancer.…
要点
- 乳腺癌幸存者研究资助远高于妇科癌症,即使考虑幸存者人数差异。
- 妇科癌症幸存者人均资助仅2.15美元,乳腺癌为9.69美元。
- 多数幸存者研究为干预性设计,聚焦治疗晚期和长期效应。
核心结论
- 美国国立卫生研究院对妇科癌症幸存者研究的资助显著低于乳腺癌,即使考虑了幸存者患病率差异。
研究设计与样本
- 回顾性队列研究,使用美国国立卫生研究院癌症幸存者办公室2017至2021财年资助数据,共纳入160项女性器官相关癌症幸存者研究资助。
主要发现
- 160项资助中144项(90%)聚焦乳腺癌,16项(10%)聚焦妇科癌症。
- 乳腺癌幸存者人均资助9.69美元,妇科癌症为2.15美元。
- 大多数幸存者研究为干预性(60%),以随机对照试验为主要设计;研究重点依次为治疗晚期和长期效应(53%)、健康促进(21%)和护理提供(16%)。
临床怎么用
- 提示应关注妇科癌症幸存者研究资源的公平分配,以优化该人群的长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cancer survivorship in the United States is rapidly rising, with a projected 50% increase by 2050, driven by improvements in treatment and increased incidence of cancers such as endometrial cancer. Along with this growth, long-term side effects create significant burdens, yet survivorship research, particularly for female-organ cancers, remains limited and imbalanced - with breast cancer studies far outnumber those for gynecologic cancers. To understand these disparities, funding patterns for survivorship research between disease sites, while accounting for differences in disease prevalence were undertaken. OBJECTIVE: To evaluate the distribution of National Institutes of Health funding for breast and gynecologic cancer survivorship research in relation to survivor populations. STUDY DESIGN: A retrospective cohort study was conducted on National Institutes of Health funded grants for breast and gynecologic cancer survivorship from fiscal years 2017 to 2021 using an existing dataset from the National Institutes of Health Office of Cancer Survivorship. Grant characteristics, including funding amount, study design, and research focus, were extracted from National Institutes of Health Reporter and ClinicalTrials.gov. Total funding and per-survivor funding were calculated using prevalence data from the Surveillance, Epidemiology, and End Results program. Descriptive statistics were applied to compare breast and gynecologic cancer survivorship research. RESULTS: Among 160 National Institutes of Health-funded grants for female organ-related cancer survivorship, 144 (90%) focused on breast cancer and 16 (10%) on gynecologic cancers. Breast cancer survivorship research received more funding ($188.35 million for 4,100,000 survivors) compared to gynecologic cancer survivorship research ($15.41 million for 796,000 survivors). Per-survivor funding was also higher for breast cancer ($9.69 per survivor) than for gynecologic cancers ($2.15 per survivor). Overall, most survivorship studies were interventional (60%), with randomized controlled trials as the predominant design. The primary study focus was on late and long-term effects of cancer treatment (53%), followed by health promotion (21%) and care delivery (16%). CONCLUSION: National Institutes of Health funding for gynecologic cancer survivorship research is substantially lower than that for breast cancer, even when accounting for survivor prevalence. The findings highlight the need for equitable resource allocation to ensure comprehensive survivorship support for gynecologic cancer survivors. Increased funding and gynecology-related research efforts are necessary to address the unique challenges faced by this population and to optimize long-term outcomes.
引用
- White P, Choi-Klier JI, Greer H, et al. Comparing National Institutes of Health funding for cancer survivorship: a spotlight on breast and gynecologic cancer. Am J Obstet Gynecol. 2026. PMID: 41856225. doi:10.1016/j.ajog.2026.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。